

February 9, 2021

Aviva Jacobs, Ph.D.
Vice President, Product Development
DxTerity Diagnostics, Inc.
19500 S. Rancho Way, Suite 116
Rancho Dominguez, CA 90220

Device: DxTerity SARS-CoV-2 RT PCR CE Test

EUA Number: EUA202120

Laboratory: DxTerity Diagnostics, Inc.

Indication: Qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens collected from any individuals determined to be appropriate for COVID-19 testing by their healthcare provider (HCP), including from individuals without symptoms of COVID-19.

This test is for use with saliva specimens that are self-collected at home by individuals using the DxTerity COVID-19 Test Collection Kit when determined to be appropriate by a HCP.

Testing is limited to the DxTerity Diagnostics, Inc. located at 19500 S. Rancho Way, Suite 116, Rancho Dominguez, CA 90220 which is certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets requirements to perform high complexity tests.

Dear Dr. Jacobs:

On August 28, 2020, based on your¹ request that the Food and Drug Administration (FDA) issued a letter authorizing the emergency use of the DxTerity SARS-CoV-2 RT PCR CE Test pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3) for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens collected from individuals suspected of COVID-19 by their healthcare provider and from any individual, including from individuals without symptoms or other reasons to suspect COVID-19. Testing was limited to DxTerity Diagnostics, Inc. located at 19500 S. Rancho Way, Suite 116, Rancho Dominguez, CA 90220 that is certified under CLIA, 42 U.S.C. §263a, and meets requirements to perform high complexity tests.

On October 30, 2020, you requested to further revise your Emergency Use Authorization (EUA).

¹ For ease of reference, this letter will use the term “you” and related terms to refer to DxTerity Diagnostics, Inc.

Based on this request, and having concluded that revising the August 28, 2020, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the August 28, 2020, letter in its entirety with the revisions incorporated.² Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product³ is now authorized for use consistent with the indication described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.⁴

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is contained in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;

² The revisions to the August 28, 2020, letter and authorized labeling include: (1) updating the indication in the letter, (2) updating the intended use to include the name of the collection kit “DxTerity COVID-19 Test Collection Kit,” (3) updating the device description and test principle to include distribution of the DxTerity COVID-19 Test Collection Kit, (4) updating the inclusivity analysis, (5) updating the shipping stability of saliva specimens during transport, (6) removing condition of authorization O in the letter issued on August 28, 2020, requiring the submission of a 30-day report, that is fulfilled, (7) minor revisions for consistency and clarification in the labeling, (8) revisions to the Conditions of Authorization to allow for authorized distributors of the DxTerity COVID-19 Test Collection Kit and for consistency with language used in more recent authorizations, and (9) updating the limitations section of the EUA Summary and healthcare provider fact sheet to add information indicating performance has not been established with all circulating variants.

³ For ease of reference, this letter will use the term “your product” to refer to the DxTerity SARS-CoV-2 RT PCR CE Test used for the indication identified above.

⁴ U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020).

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.⁵

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a qualitative test for the detection of nucleic acid from SARS-CoV-2 in saliva specimens collected from any individuals determined to be appropriate for COVID-19 testing by their HCP, including from individuals without symptoms of COVID-19.

This test is for use with saliva specimens that are self-collected at home (unobserved) using the DxTerity COVID-19 Test Collection Kit when determined to be appropriate by a HCP. Testing is limited to DxTerity Diagnostics, Inc. located at 19500 S. Rancho Way, Suite 116, Rancho Dominguez, CA 90220 which is certified under CLIA and meets requirements to perform high complexity tests.

The SARS-CoV-2 nucleic acid is generally detectable in saliva specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 nucleic acid; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The “COVID-19 Questionnaire,” is used in making patient management decisions. Negative results obtained from saliva specimens from individuals without symptoms should be considered as presumptive and confirmed with a preferred specimen type or different molecular assay validated for testing saliva, if necessary for patient management.

The DxTerity COVID-19 Test Collection Kit contains the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device, biohazard specimen bag with absorbent material, pre-labeled return shipping box along with Instructions for Use for shipping the samples on the same day of collection for next day delivery to the laboratory. Saliva specimens must be transported and stored at ambient temperature and tested within 72 hours of collection. Specimens are received at the clinical laboratory for testing with the DxTerity SARS-CoV-2 RT-PCR CE Test.

To use your product, SARS-CoV-2 nucleic acid is first extracted and purified from the saliva specimen. The purified nucleic acid is then reverse transcribed into cDNA followed by PCR

⁵ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

amplification and detection using an authorized capillary electrophoresis instrument described in the authorized labeling (described below).

The product uses all commercially sourced materials or other authorized materials and authorized ancillary reagents commonly used in clinical laboratories as described in the authorized labeling.

Your product requires the following control materials, or other authorized control materials (as may be requested for inclusion under Condition R below), that are processed in the same way as the patient specimens and are required to be included with each batch of specimens tested with your product. All controls listed below must generate expected results in order for a test to be considered valid, as outlined in the authorized labeling:

- Negative Control – nuclease-free water combined with stabilization buffer from the saliva collection device used to monitor for cross-contamination during RNA extraction and RT-PCR.
- Positive Control – a dilution of the Synthetic SARS-CoV-2 RNA Control in positive control dilution buffer used to monitor the integrity of the RT-PCR reagents and process.
- Internal Control – a primer set for RNase P amplifies the RNase P gene in the saliva sample, used to monitor the integrity of nucleic acid extraction and PCR for each specimen.

The labeling entitled “DxTerity Test Kit Instructions for Use,” the EUA Summary (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas>), the “COVID-19 Questionnaire,” the “DxTerity Receiving and Accessioning of Clinical Specimens,” the “Automated 30 min RNA Extraction from Stabilized Saliva Samples,” the “DxTerity SARS-CoV-2 RT-PCR-CE Assay Procedure,” and the following fact sheets pertaining to the emergency use, which is required to be made available as set forth in the Conditions of Authorization (Section IV), are collectively referenced as “authorized labeling”:

- Fact Sheet for Healthcare Providers: DxTerity Diagnostics, Inc. – DxTerity SARS-CoV-2 RT-PCR CE Test
- Fact Sheet for Patients: DxTerity Diagnostics, Inc. – DxTerity SARS-CoV-2 RT-PCR CE Test

The above described product, with the authorized labeling provided as set forth in the Conditions of Authorization (Section IV), is authorized to be used under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

The DxTerity COVID-19 Test Collection Kit with the “DxTerity Test Kit Instructions for Use” is authorized to be distributed and used as part of the above described product as set forth in this EUA.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of

Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, and storage of your product.

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

DxTerity Diagnostics, Inc. (You) and Authorized Distributor(s)⁶

- A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributors must make available all instructions related to the self-collection of saliva specimens (“DxTerity Test Kit Instructions for Use”) using the DxTerity COVID-19 Test Collection Kit both in the shipped kit and on your website.

⁶ “Authorized Distributor(s)” are identified by you, DxTerity Diagnostics, Inc., in your EUA submission as an entity allowed to distribute the DxTerity COVID-19 Test Collection Kit.

- C. You and authorized distributor(s) must make available on your website(s), if applicable, the Fact Sheet for Healthcare Providers and the Fact Sheet for Patients.
- D. Through a process of inventory control, you and authorized distributor(s) must maintain records of the numbers and locations to which the DxTerity COVID-19 Test Collection Kit is distributed.
- E. You and authorized distributor(s) must maintain customer complaint files concerning the DxTerity COVID-19 Test Collection Kit on record. You will report to FDA any significant complaints about usability or deviations from the established performance characteristics of the product of which you become aware.
- F. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.
- G. You and authorized distributor(s) must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records must be made available to FDA for inspection upon request.

DxTerity Diagnostics, Inc. (You)

- H. You must notify FDA of any authorized distributor(s) of the DxTerity COVID-19 Test Collection Kit, including the name, address, and phone number of any authorized distributor(s).
- I. You must provide authorized distributor(s) with a copy of this EUA and communicate to authorized distributor(s) any subsequent authorized revisions that might be made to this EUA and the authorized accompanying materials.
- J. Your product must be accompanied by the labeling entitled EUA Summary, the “COVID-19 Questionnaire,” the “DxTerity Receiving and Accessioning of Clinical Specimens,” the “Automated 30 min RNA Extraction from Stabilized Saliva Samples,” the “DxTerity SARS-CoV-2 RT-PCR-CE Assay Procedure.”
- K. You must inform relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product and authorized labeling.
- L. You must notify the relevant public health authorities of your intent to run your product.
- M. You must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- N. You must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be

used, which may include mass media.

- O. You must use your product as outlined in the authorized labeling. Deviations from the authorized laboratory procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and/or authorized materials required to use your product are not permitted.
- P. When testing authorized specimens self-collected using home-collection kits authorized for use with your product you must follow any specimen accessioning protocols provided with the self-collection kit when accepting specimens for testing.
- Q. You must collect information on the performance of your product. You must report to Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) (via email: CDRH-EUA-Reporting@fda.hhs.gov) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which you become aware.
- R. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the DMD/OHT7-OIR/OPEQ/CDRH and require appropriate authorization from FDA prior to implementation.
- S. You will evaluate the analytical limit of detection and assess traceability of your product with any FDA-recommended reference material(s), if requested by FDA⁷. After submission to and concurrence with the data by FDA, FDA will update the EUA Summary to reflect the additional testing.
- T. You will further evaluate the negative percent agreement of your product in an FDA agreed upon post authorization clinical evaluation study within 3 months of the date of this letter (unless otherwise agreed to with DMD/OHT7-OIR/OPEQ/CDRH). After submission to FDA and DMD/OHT7-OIR/OPEQ/CDRH's review of and concurrence with the data, you will update authorized labeling to reflect the additional testing. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.
- U. You must have a process in place to track adverse events, including any occurrence of

⁷ Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material. FDA may request, for example, that you perform this study in the event that we receive reports of adverse events concerning your product.

false results with your product, and report any such events to FDA pursuant to 21 CFR Part 803.

- V. All laboratory personnel using your product must be appropriately trained in molecular techniques and use appropriate laboratory and personal protective equipment when handling this product, and use your product in accordance with the authorized laboratory procedure.
- W. Upon request you will conduct post-authorization studies and/or data analysis concerning the performance of saliva specimens with your authorized test. Such studies and/or data analysis will be agreed upon between you and FDA. After submission to FDA and review of the data, FDA will consider whether additional action is appropriate, such as revision or revocation of the EUA.

Conditions Related to Printed Materials, Advertising and Promotion

- X. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and the requirements set forth in section 502(a), (q)(1), and (r) of the Act and FDA implementing regulations.
- Y. No descriptive printed matter, advertising, or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.
- Z. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall clearly and conspicuously state that:
 - This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by DxTerity Diagnostics, Inc. located at 19500 S. Rancho Way, Suite 116, Rancho Dominguez, CA 90220;
 - This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
 - The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

RADM Denise M. Hinton
Chief Scientist
Food and Drug Administration

Enclosure

Technical correction: February 22, 2021